Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

New long-term data of the investigational therapy icotrokinra show that it is able to achieve site-specific clear or almost clear skin in patients with plaque psoriasis, according to results of the ...

In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

Other Phase 3 studies in the development program include ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), which are evaluating the efficacy and safety of icotrokinra compared with ...